Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchDeuremidevirDeuremidevir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Deuremidevir for COVID-19
2 studies from 62 scientists
1,432 patients in 1 country
Statistically significant lower risk for recovery and viral clearance.
2 studies from 2 independent teams (both from the same country) show statistically significant improvements.
COVID-19 Deuremidevir studies. Feb 2024. c19early.org
0 0.5 1 1.5+ All studies 11% Viral clearance 15% RCTs 67% Early 11% Favorsdeuremidevir Favorscontrol
Recent:
Ma
Liu
Zheng
Qian
Shen
Xiao
Fan.
Deuremidevir has been officially adopted in 2 countries. Submit updates/corrections.
Feb 20
Covid Analysis Deuremidevir for COVID-19: real-time meta analysis of 2 studies
Statistically significant lower risk is seen for recovery and viral clearance. 2 studies from 2 independent teams (both from the same country) show statistically significant improvements. Meta analysis using the most serious outcome repor..
Jan 18
Zheng et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2024.107096 Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis
Systematic review and network meta-analysis of 160 studies involving over 900,000 COVID-19 patients assessing the efficacy and safety of small-molecule antivirals. For VV116, significant benefit was found for viral clearance.
Nov 30
2023
Fan et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(23)00577-7 Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
15% faster recovery (p=0.01) and 24% improved viral clearance (p=0.006). RCT 1,369 patients with mild-to-moderate COVID-19 showing significantly faster time to sustained clinical symptom resolution (median 10.9 days vs 12.9 days) with VV116 compared to placebo. VV116 was given as 0.6g BID day 1 followed by 0.3..
Nov 23
2023
Liu et al., Viruses, doi:10.3390/v15122295 Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses
In Vitro study showing the remdesivir derivative VV116 exhibits broad-spectrum inhibition against human coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43) and animal coronaviruses (MHV, FIPV, FECV, CCoV) without cytotoxicity. Through time-of..
Jul 31
2023
Ma et al., Progress in Pharmaceutical Sciences, doi:10.20053/j.issn1001-5094.2023.07.003 Clinical Research and Development of Deuremidevir Hydrobromide Tablets for the Treatment of COVID-19
Review of the research and development of deuremidevir, an oral nucleoside analog targeting the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, for the treatment of COVID-19. Deuremidevir was approved for marketing in China in January ..
Jul 7
2023
Xiao et al., Medicine, doi:10.1097/MD.0000000000034105 The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review
Systematic review of 3 VV116 studies with 1,044 participants. Authors conclude that VV116 had minimal adverse events and was not inferior in symptomatic alleviation when compared with paxlovid. Authors note that more research into the saf..
Dec 28
2022
Cao et al., New England Journal of Medicine, doi:10.1056/NEJMoa2208822 VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
RCT 771 hospitalized patients with mild-to-moderate COVID-19 and high risk of progression showing non-inferior time to sustained clinical recovery with 5 days of VV116 compared to 5 days of paxlovid. No deaths or progression to severe dis..
Jun 2
2022
Shen et al., Emerging Microbes & Infections, doi:10.1080/22221751.2022.2078230 An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
11% faster viral clearance (p<0.0001). Prospective 136 hospitalized mild to moderate COVID-19 patients in China, showing faster viral clearance with VV116 treatment. 60 patients received VV116 300mg twice daily for 5 days plus standard care, while 76 patients received only sta..
Mar 16
2022
Qian et al., Acta Pharmacologica Sinica, doi:10.1038/s41401-022-00895-6 Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
Phase 1 study of the safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog prodrug, in healthy subjects. A single ascending dose study, multiple ascending dose study, and food effect study were conducted sequentia..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit